StockData
ProMIS Neurosciences Inc. logo

ProMIS Neurosciences Inc. (PMN) shareholders

PMNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$3.21−0.10 (-3.02%)

Close on Nov 17, 2026Market cap $28.79MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
71.4%
6M of 9M shares
Institutional holders
27
5 new, 2 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
11 buys · 0 sales
Net bought $8.88M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Jonathan Shafmaster
Joint filing with Shaf QIC LLC (10.01%)
10,534,63910.01%13G (passive) amendmentJul 29, 2025
Jeremy M. Sclar
Joint filing with Jeremy M. Sclar 2012 Irrevocable Family Trust (13.60%)
9,511,93016.90%13G (passive) amendmentSep 30, 2025
Ally Bridge MedAlpha Master Fund L.P.
Joint filing with ABG Management Ltd. (11.30%), Ally Bridge Group (NY) LLC (11.30%) and 1 more
6,070,40511.30%13D (active) amendmentJan 29, 2026
Title 19 Promis
Joint filing with Michael S. Gordon (9.00%)
4,886,1089.00%13G (passive) amendmentJun 30, 2025
Dr. Jeffrey R. Jay, M.D.
Joint filing with Great Point Partners, LLC (9.99%), Ms. Lillian Nordahl (9.99%)
3,334,5209.99%13G (passive) amendmentDec 31, 2024
Sphera Funds Management Ltd.
Joint filing with Sphera Global Healthcare GP Ltd. (5.51%), Sphera Global Healthcare Management LP. (5.51%)
3,122,0905.51%13G (passive) amendmentSep 30, 2025
Steven Boyd
Joint filing with Armistice Capital, LLC (7.68%)
2,509,9777.68%13G (passive) amendmentDec 31, 2024
Fan Yu
Joint filing with ABG V-SIV IX Limited (7.10%), Ally Bridge Group Global Life Science Capital Partners V, L.P. (7.10%) and 5 more
1,644,39717.00%13D (active) amendmentFeb 3, 2026
Janus Henderson Group PLC1,292,75714.40%13G (passive)Mar 31, 2026
Trails Edge Biotechnology Master Fund, LP
Joint filing with Trails Edge Capital Partners, LP (9.90%), Ortav Yehudai (9.90%)
933,4779.90%13G (passive)Feb 3, 2026
Deep Track Capital, LP
Joint filing with David Kroin (9.99%), Deep Track Biotechnology Master Fund, Ltd. (7.79%)
902,5619.99%13G (passive)Jan 30, 2026
Great Point Partners, LLC
Joint filing with Dr. Jeffrey R. Jay, M.D. (7.66%), Ms. Lillian Nordahl (7.66%)
736,8817.66%13G (passive) amendmentJun 30, 2026
Wellington Management Company LLP
Joint filing with Wellington Management Group LLP (7.80%), Wellington Group Holdings LLP (7.80%) and 1 more
696,3787.80%13G (passive) amendmentJun 30, 2026
Wellington Biomedical Innovation Master Investors (Cayman) II, L.P.696,3787.80%13G (passive) amendmentJun 30, 2026
Ms. Lillian Nordahl
Joint filing with Great Point Partners, LLC (9.99%), Dr. Jeffrey R. Jay, M.D. (9.99%)
409,6489.99%13G (passive) amendmentDec 31, 2025
Sphera Global Healthcare Management LP.
Joint filing with Sphera Funds Management Ltd. (7.78%), Sphera Global Healthcare GP Ltd. (7.78%)
180,6987.78%13G (passive) amendmentDec 31, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of PMNValueChange% of portfolio
Jupiter Topco LLC1,292,75714.42%$17.01MNew0.01%
Deep Track Capital, LP835,6559.32%$11.00M–0.16%
Wellington Management Group Llp696,3787.77%$9.16M–0.00%
Ally Bridge Group (NY) LLC620,3196.92%$8.16M+206,1007.22%
Trails Edge Capital Partners, LP557,1036.21%$7.33M–1.16%
Woodline Partners LP441,9114.93%$5.82M+46,6160.02%
Yu Fan329,7603.68%$4.34M–4.02%
Sphera Funds Management Ltd.325,5913.63%$4.28M–0.56%
Squadron Capital Management LLC324,9773.62%$4.28M–1.33%
Ikarian Capital, LLC205,0002.29%$2.70M+150,0000.29%
Ameriprise Financial Inc185,7002.07%$2.44MNew0.00%
Adage Capital Partners Gp, L.L.C.164,2751.83%$2.16M+25,0000.00%
683 Capital Management, LLC95,0001.06%$1.25M+2,1500.06%
ADAR1 Capital Management, LLC92,8501.04%$1.22M−2,5000.06%
Great Point Partners LLC86,1500.96%$1.13M−285,2520.21%
Boothbay Fund Management, LLC62,0780.69%$816.95K+46,0350.01%
Millennium Management LLC56,0450.62%$737.55K−21,8760.00%
Bank Of Montreal /Can/11,3710.13%$149.64KNew0.00%
Seven Fleet Capital Management LP10,6000.12%$139.50K–0.02%
Morgan Stanley7,5590.08%$99.48KNew0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026276M71.4%5 / 66 / 22M0M
Q1 2026256M68.5%18 / 33 / 26M0M
Q4 202590M3.0%2 / 23 / 160M0M
Q3 2025230M4.5%8 / 42 / 30M0M
Q2 2025190M3.8%6 / 24 / 30M0M
Q1 2025160M4.2%1 / 24 / 30M0M
Q4 2024180M4.3%2 / 15 / 20M0M
Q3 2024180M4.5%5 / 51 / 30M0M
Q2 2024160M1.5%2 / 03 / 20M0M
Q1 2024160M1.5%4 / 04 / 30M0M
Q4 2023150M1.5%1 / 31 / 00M0M
Q3 2023140M1.3%3 / 15 / 20M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

2 funds held PMN in Q2 2026, 0% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of PMNValue% of fundAs of
Fidelity Nasdaq Composite Index Fund5,6760.06%$61.36K0.00%May 31, 2026
Blackstone Alternative Multi-Strategy Fund-404-0.00%-$5.32K-0.00%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Neil CashmanChief Scientific Officer, Director19,3180.22%Nov 3, 2026
Neil K. WarmaChief Executive Officer, Director6,1830.07%May 22, 2026
Ivana RubinoChief Commercial Officer––Oct 6, 2026
Johanne KaplanChief Development Officer6,2210.07%Aug 7, 2026
Max A. MilburyPrincipal Accounting Officer8,4090.09%May 22, 2026
Larry Douglas AltstielChief Medical Officer––Sep 24, 2025
Eugene WilliamsDirector40,2130.45%Nov 6, 2026
Josh Mandel-BrehmDirector––May 22, 2026
Madge K. ShafmasterDirector208,3332.32%May 22, 2026
Slanix Paul AlexDirector6,058,73867.56%May 22, 2026
William W. WymanDirector62,9370.70%May 22, 2026
Patrick D. KirwinDirector10,0930.11%Apr 23, 2026
Global Life Science Capital Partners V. GP Ltd ABG10% owner––Feb 25, 2026
Ally Bridge Group Global Life Science Capital Partners V, L.P.10% owner––Feb 25, 2026
V-SIV IX Ltd ABG10% owner––Feb 25, 2026
V-SIV X. Ltd ABG10% owner––Feb 25, 2026
ABG Global Life Science Capital Partners V GP, L.P.10% owner943,09010.52%Feb 25, 2026
Fan Yu10% owner943,09010.52%Feb 5, 2026
Management Ltd. ABG10% owner––Feb 5, 2026
Bridge Group (NY) LLC Ally10% owner––Feb 5, 2026
Bridge MedAlpha Master Fund L.P. Ally10% owner6,058,73867.56%Feb 5, 2026
M. Sclar 2012 Irrevocable Family Trust Jeremy10% owner1,617,43718.04%Sep 30, 2025
Jeremy M. Sclar10% owner7,246,29680.80%Sep 8, 2025
19 Promis Title–2,435,02927.15%Aug 14, 2025
Jonathan Shafmaster10% owner––Aug 14, 2025
QIC LLC Shaf10% owner5,184,76057.82%Aug 14, 2025
Michael S. Gordon–2,435,02927.15%Aug 14, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Eugene Williams
Director
Nov 4, 2026Buy+26,500$3.43$90.90K40,213
Neil Cashman
Chief Scientific Officer, Director
Nov 2, 2026Buy+10,000$3.86$38.60K14,532
Eugene Williams
Director
Oct 30, 2026Buy+1,316$3.99$5.25K13,713
Johanne Kaplan
Chief Development Officer
Aug 5, 2026Buy+2,280$13.30$30.32K6,221
Patrick D. Kirwin
Director
Apr 22, 2026Buy+4,000$11.33$45.32K4,653
Eugene Williams
Director
Mar 5, 2026Buy+2,000$24.40$48.80K12,397
Eugene Williams
Director
Mar 4, 2026Buy+2,000$24.00$48.00K10,397
Eugene Williams
Director
Mar 3, 2026Buy+1,000$21.89$21.89K8,397
Eugene Williams
Director
Mar 2, 2026Buy+1,000$22.53$22.53K7,397
Johanne Kaplan
Chief Development Officer
Feb 19, 2026Buy+1,629$15.35$25.01K3,941
Max A. Milbury
–
Feb 3, 2026Award+6,595$12.13$80.00K8,409
Johanne Kaplan
Chief Development Officer
Feb 3, 2026Award+2,060$12.13$24.99K2,312
Neil Cashman
Chief Scientific Officer, Director
Feb 3, 2026Award+4,122$12.13$50.00K4,122
Patrick D. Kirwin
Director
Feb 3, 2026Award+3,050$12.13$37.00K5,135
Neil K. Warma
Chief Executive Officer, Director
Feb 3, 2026Award+6,183$12.13$75.00K6,183
Fan Yu
10% owner
Feb 3, 2026Buy+700,741$12.13$8.50M943,090
Max A. Milbury
–
Oct 3, 2025Buy+30,392$0.49$14.89K45,389
M. Sclar 2012 Irrevocable Family Trust Jeremy
10% owner
Jul 25, 2025Option exercise+697,674––3,012,785
M. Sclar 2012 Irrevocable Family Trust Jeremy
10% owner
Jul 25, 2025Option exercise+697,674––2,315,111
M. Sclar 2012 Irrevocable Family Trust Jeremy
10% owner
Jul 25, 2025Option exercise+697,674––3,710,459
Jeremy M. Sclar
10% owner
Jul 25, 2025Option exercise+697,674––3,710,459
Jeremy M. Sclar
10% owner
Jul 25, 2025Option exercise+697,674––2,315,111
Jeremy M. Sclar
10% owner
Jul 25, 2025Option exercise+697,674––3,012,785
19 Promis Title
10% owner
Jul 25, 2025Option exercise+119,800––2,435,029
19 Promis Title
10% owner
Jul 25, 2025Option exercise+119,800––2,315,229
19 Promis Title
10% owner
Jul 25, 2025Option exercise+119,800––2,195,429
Michael S. Gordon
10% owner
Jul 25, 2025Option exercise+119,800––2,315,229
Michael S. Gordon
10% owner
Jul 25, 2025Option exercise+119,800––2,195,429
Michael S. Gordon
10% owner
Jul 25, 2025Option exercise+119,800––2,435,029
Michael S. Gordon
10% owner
Jun 30, 2025Sale−93,223––0
Michael S. Gordon
–
Mar 13, 2025Other−48,333––0
Neil Cashman
Chief Scientific Officer, Director
Feb 10, 2025Buy+15,000$0.97$14.55K16,617
Madge K. Shafmaster
Director
Sep 24, 2024Buy+70,000$1.30$91.00K208,333
Madge K. Shafmaster
Director
Sep 23, 2024Buy+70,000$1.28$89.60K138,333
Madge K. Shafmaster
Director
Sep 20, 2024Buy+60,000$1.25$75.00K68,333
Michael S. Gordon
10% owner
Sep 17, 2024Buy+16,292$1.40$22.81K93,223
Michael S. Gordon
10% owner
Sep 16, 2024Buy+76,931$1.22$93.86K76,931
Patrick D. Kirwin
Director
Aug 14, 2024Buy+10,000$1.25$12.50K62,983
19 Promis Title
10% owner
Jul 31, 2024Buy+465,116––1,575,629
19 Promis Title
10% owner
Jul 31, 2024Conversion+500,000––2,075,629
Jeremy M. Sclar
10% owner
Jul 31, 2024Conversion+150,000––1,155,726
Jeremy M. Sclar
10% owner
Jul 31, 2024Buy+697,674––1,467,437
Jeremy M. Sclar
10% owner
Jul 31, 2024Conversion+150,000––1,617,437
Michael S. Gordon
10% owner
Jul 31, 2024Conversion+500,000––2,075,629
Michael S. Gordon
10% owner
Jul 31, 2024Buy+465,116––1,575,629
Max A. Milbury
Principal Accounting Officer
Aug 23, 2023Award+13,297––14,997
Gavin T. Malenfant
Chief Operating Officer
Aug 23, 2023Award+2,660––2,660
Neil Cashman
Chief Scientific Officer, Director
Aug 23, 2023Award+10,643––113,304
Patrick D. Kirwin
Director
Aug 23, 2023Award+11,000––52,983
Gail M. Farfel
Chief Executive Officer, Director
Aug 23, 2023Award+53,192––55,192
Eugene Williams
Director
Dec 16, 2022Buy+1,000$4.64$4.64K159,930
Eugene Williams
Director
Dec 16, 2022Buy+1,000$4.65$4.65K158,930
Patrick D. Kirwin
Director
Dec 15, 2022Buy+2,000$4.51$9.02K27,998
Gail M. Farfel
Chief Executive Officer
Dec 14, 2022Buy+1,000$4.94$4.94K2,000
Patrick D. Kirwin
Director
Dec 13, 2022Buy+1,000$4.87$4.87K25,998
Eugene Williams
Director
Dec 12, 2022Buy+1,000$5.08$5.08K157,930
Patrick D. Kirwin
Director
Dec 9, 2022Buy+1,000$4.98$4.98K24,998
Eugene Williams
Director
Dec 7, 2022Buy+1,000$5.49$5.49K156,930
Gail M. Farfel
Chief Executive Officer
Dec 6, 2022Buy+1,000$5.70$5.70K1,000
Eugene Williams
Director
Dec 2, 2022Buy+1,000$5.98$5.98K155,930

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
3.06%
0M shares short
Days to cover
1.5
At 0M shares a day
Change since last report
+11.8%
From 0M shares
Short volume, 20 days
53.2%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of ProMIS Neurosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 5,804 shares on Sep 10, 2026 over the last 90 days.

See a number that looks wrong?